Last reviewed · How we verify
Omvoh (MIRIKIZUMAB)
Omvoh (generic name: MIRIKIZUMAB) is a Interleukin-23 Antagonist [EPC] Monoclonal antibody drug developed by Eli Lilly Nederland B.V.. It is currently FDA-approved (first approved 2023) for Ulcerative Colitis, Crohn's Disease.
MIRIKIZUMAB blocks the activity of Interleukin-23, a protein involved in inflammation.
Mirikizumab is an interleukin-23 inhibitor, classified as an antibody inhibitor, used to treat various chronic inflammatory conditions, including pouchitis, ulcerative colitis, and Crohn's disease. It is administered via intravenous or subcutaneous routes, and has also been studied in combination with vedolizumab.
At a glance
| Generic name | MIRIKIZUMAB |
|---|---|
| Sponsor | Eli Lilly Nederland B.V. |
| Drug class | Interleukin-23 Antagonist [EPC] |
| Target | Interleukin-23 subunit alpha |
| Modality | Monoclonal antibody |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2023 |
| Annual revenue | 800 |
Mechanism of action
Think of Interleukin-23 like a messenger that tells the body to increase inflammation. When MIRIKIZUMAB blocks this messenger, it helps reduce inflammation in the body, which can help treat conditions like ulcerative colitis.
Approved indications
- Ulcerative Colitis
- Crohn's Disease
Common side effects
- Infections
- Infections
- Upper respiratory tract infections
Serious adverse events
- Serious infections (intestinal sepsis, listeria sepsis, pneumonia)
- COVID-19 pneumonia
- ALT ≥5X ULN
- AST ≥5X ULN
- Infusion-related hypersensitivity reactions
Drug interactions
- CYP450 substrates
Key clinical trials
- A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (PHASE3)
- A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) (PHASE3)
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight (PHASE3)
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (PHASE3)
- A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease (PHASE2)
- A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease (PHASE2)
- A Study of Mirikizumab Solution (LY3074828) in Healthy Participants (PHASE1)
- A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omvoh CI brief — competitive landscape report
- Omvoh updates RSS · CI watch RSS
- Eli Lilly Nederland B.V. portfolio CI
Frequently asked questions about Omvoh
What is Omvoh?
How does Omvoh work?
What is Omvoh used for?
Who makes Omvoh?
What is the generic name of Omvoh?
What drug class is Omvoh in?
When was Omvoh approved?
What development phase is Omvoh in?
What are the side effects of Omvoh?
What is Omvoh's annual revenue?
What does Omvoh target?
Related
- Drug class: All Interleukin-23 Antagonist [EPC] drugs
- Target: All drugs targeting Interleukin-23 subunit alpha
- Manufacturer: Eli Lilly Nederland B.V. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Ulcerative Colitis
- Indication: Drugs for Crohn's Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing